BofA Global Research raises Ligand Pharmaceuticals price objective to $406 from $388
LGND•BofA Global Research raised its price objective for Ligand Pharmaceuticals to $406 from $388.
Related News
ANI Pharmaceuticals announces the launch of duloxetine delayed-release capsules
ANIP•
Strive buys 4,045 bitcoin, lifting holdings to 36,818
ASST•
AMC Entertainment Holdings, Inc.: B. Riley raises target price to $3.25 from $2.50
AMC•
Estée Lauder: Jefferies raises target price to $120 from $100
EL•
FDA accepts UroGen's UGN-103 application for bladder cancer treatment
URGN•